Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending May 2012. The report details a specific corporate action regarding share repurchases executed on May 14, 2012, pursuant to shareholder authority granted at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. It focuses exclusively on capital structure and share repurchase activity.
- Shares Purchased: 1,400,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,422 pence per share; lowest price paid was 1,406.5 pence per share.
- Treasury Holdings (Settled): 526,797,927 shares (9.47% of total issued share capital).
- Treasury Holdings (Including Unsettled): 530,347,927 shares (10.53% of current total voting rights).
- Shares in Issue (Excluding Treasury): 5,037,764,283 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 1,400,000 shares on May 14, 2012. This transaction increased the proportion of shares held in Treasury from the prior level to 9.47% of issued capital (or 10.53% of voting rights when including unsettled trades).
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules and explicitly states it does not constitute an offer to purchase securities.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (526,797,927 settled) against the company's latest annual report.
- Confirm the total issued share capital excluding treasury shares (5,037,764,283) for accurate voting rights calculations.
- Review the remaining authorization for share buybacks following this transaction.
- Note that this filing does not contain financial performance data; refer to Form 20-F for revenue and profit metrics.